Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Technology Scientific & Technical Instruments
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Sona Nanotech Inc
Bullboard Posts
User Avatar Image
(124)
•••
Post by Awsm11on Oct 07, 2020 10:51am
156 Views
Post# 31679769

Preliminary Results

Preliminary Resultsfrom

https://www.cbc.ca/news/politics/health-canada-antigen-test-abbott-1.5751939

"Preliminary results from a clinical study conducted by Abbott on 241 samples found that the Panbio COVID-19 Ag test has a sensitivity rate of 93.3 per cent in people suspected of having been exposed to COVID-19 or showing symptoms in the past seven days."

Preliminary results only??? and they get approval?  

SONA has multi layered testing, scrutiny and results from top tier organizations.

Our Results are not PRELIMINARY

Another fumble by the govt.

Typical of HC as they just want to piggy back on anything FDA has approved and are not able to make their own decision on a Canadian home made test that could save the world..

Get with it Trudeau and company.

This is in your own back yard.







Bullboard Posts
Dealroom for high-potential pre-IPO opportunities